Revenues of $3.5 million, Weaker Gross Margin, and Net Loss MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2025 ended June 30, 2025 (“Q3” and “YTD”). Sales for Q3 were down for both Antigens and QAPs™, while YTD Antigens were up and QAPs were down YTD. Management DiscussionResults for Q3 were disappointing, impacted by two key events, cancellation of test-development programs by a key customer and the decline in sales to China. YTD recurring revenues of $14.4 million are slightly lower than prior year. Financial strength remains, with strong cash & equivalents and overall liquidity. New business development is proceeding well but...

VALUE Phase III Trial of EscharEx® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. “We continue to execute across our clinical, commercial, and operational objectives,” said Ofer Gonen, Chief Executive Officer of MediWound. “The VALUE Phase III trial of EscharEx®...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic BDC, Inc. (“LIEN” or the “Company”) (NASDAQ: LIEN), a specialty finance company that has elected to be regulated as a business development company, today announced its financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights and Subsequent ActivityTotal gross investment income of $13.1 million Net investment income of $7.7 million, or $0.34 per weighted average share outstanding Total investment portfolio of $307.5 million at fair value Net asset value (“NAV”) per share was $13.23 on June 30, 2025 Declared a dividend of $0.34 per share for the quarter ending September 30, 2025 payable on October 10, 2025 to shareholders of record of September 29, 2025 Funded nine portfolio companies with $39.1 million in aggregate par value during...

Thomas E. Hogan Named CEO ARR grew 21% to $418.9 million; Revenue grew 18% to $113.3 million Net income of $19.5 million supports non-GAAP net income of $30.8 million and adjusted EBITDA of $27.9 million, 24.6% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced financial results for the three and six months ending June 30, 2025 and the appointment of Thomas E. Hogan as the Company’s CEO. “Cellebrite delivered a strong balance of top-line growth, profitability and cash flow,” stated Thomas E. Hogan, Cellebrite’s CEO. “The Company converted 18% revenue growth into a 29% increase in adjusted EBITDA while free cash flow grew 133% to $29.0 million,...

Record Quarterly Revenue of $2.77 million Post-Quarter ETH Holdings Surpass $321 Million SILVER SPRING, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced its financial results for the three and six months ended June 30, 2025 (“Q2 2025”). Further, the Company updated its investor presentation, which can be found on its refreshed website at www.btcs.com. “BTCS delivered record quarterly and year-to-date revenues in Q2 2025, surpassing our prior annual revenue record in the first six months of 2025,” said Charles Allen, CEO of BTCS. “Builder+ operations focused on Ethereum drove a 394% year-over-year revenue increase. These achievements are a testament to our successful execution of...

PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of PRT3789, a once weekly IV SMARCA2 degrader, has been completed; Company to provide final data by year end 2025 Prelude is advancing a development candidate for its oral KAT6A degrader program and remains on track to file an IND in the first half of 2026 Current cash runway into the second quarter of 2026 with $77.3 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2025  WILMINGTON, Del., Aug. 14, 2025 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial...

– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – – Planning to engage with U.S. Food & Drug Administration (FDA) in the second half of 2025 to discuss potential registrational pathways for WTX-124 in advanced or metastatic cutaneous melanoma – – Phase 1b/2 clinical trial of WTX-330 is actively enrolling, with anticipated determination of dosing regimen by the end of 2025 – – Company announces WTX-1011, its first INDUCER™ T-cell engager development candidate, targeting STEAP1 – WATERTOWN, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering...

Strong Bookings and continuing SaaS Revenue growth Q2 2025 Highlights 1  Revenue (in $ millions)  SaaS Subscription Recurring TotalReported Y/Y growth Reported Y/Y growth Reported Y/Y growth$7.9 13.1% $10.9 4.0% $15.7 (6.9)% SaaS ARR up 12.5% Y/Y to $31.7 million; Total ARR up 3% Y/Y to $43.8 million; SaaS NRR of 107%; Bookings up 33% Y/Y to 17.1 million; Adjusted EBITDA margin of 15.3% or $2.4 million; Gross profit margin of 58%; and Recurring Revenue at 70% of Total Revenue.CALGARY, Alberta, Aug. 14, 2025 (GLOBE NEWSWIRE) — Sylogist Ltd. (TSX: SYZ) (“Sylogist” or the “Company”), a leading public sector SaaS company, today announced its results for the second quarter of fiscal 2025, ended June 30, 2025. “I am very pleased with our Q2 performance,” said Bill Wood, CEO of Sylogist. “In...

OMAHA, NE, Aug. 14, 2025 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2025. Highlights for the second quarter ended June 30, 2025 include:Total revenue was $16.1 million, 5% lower than the second quarter of 2024.   Online revenue was $10.4 million, representing 65% of total revenue and down 7% compared to the second quarter of 2024. Gross margin was 42.8% compared to 44.8% during the second quarter of 2024. Net income for the second quarter of 2025 was $1.7 million compared to $2.6 million during the same period last year, with merger and acquisition related expense associated with the Irwin Naturals transaction accounting for most...

– Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) – OLC pivotal study data, published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrated OLC was well tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden – Ended Q2 with $22.3 million of cash with expected runway into the second half of 2026 LOS ALTOS, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended June 30, 2025, and provided a business update. “Our team has...